MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, and the company currently has three approved medicines and a near-term approval for its ALK2 inhibitor. The recent acquisition of zilurgisertib, despite the missing pivotal endpoint, has improved the company's valuation as it addresses the unmet need of patients with fibrodysplasia ossificans progressiva. The company's upcoming clinical data readouts and its diverse pipeline with promising candidates make it a top pick with a positive outlook.

Mirum Pharmaceuticals is a clinical-stage biotech company that specializes in developing treatments for rare liver diseases. Despite having three approved medicines and a promising pipeline, Mirum has yet to generate substantial revenue. Additionally, the company's lead candidate, Livmarli, is only approved for a specific type of pruritus and may face competition from other drugs in development. Lastly, Mirum's financials show that their operating expenses have increased, potentially putting strain on their finances in the future.